4589 On Other Exchanges
Symbol
Exchange
4589 is not on other exchanges.

acucela inc (4589) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACUCELA INC (4589)

Related News

No related news articles were found.

acucela inc (4589) Related Businessweek News

No Related Businessweek News Found

acucela inc (4589) Details

Acucela Inc., a clinical stage ophthalmology company, identifies and develops therapeutic products to treat and slow the progression of sight-threatening ophthalmic diseases in the United States. Its lead investigational drug candidate is the Emixustat hydrochloride (Emixustat), which is in Phase IIb/III clinical trial for the treatment of geographic atrophy associated with dry age-related macular degeneration. The company also offers OPA-6566, an adenosine A2a receptor agonist that has completed Phase I/II clinical trial for the treatment of glaucoma. It has a co-development and collaboration agreement with Otsuka Pharmaceutical Co., Ltd. for Emixustat and OPA-6566. The company was founded in 2002 and is headquartered in Seattle, Washington.

49 Employees
Last Reported Date: 03/11/16
Founded in 2002

acucela inc (4589) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $515.0K
Chief Financial Officer, Secretary and Treasu...
Total Annual Compensation: $261.3K
Compensation as of Fiscal Year 2015.

acucela inc (4589) Key Developments

Acucela Inc.(TSE:4589) added to S&P Global BMI Index

Acucela Inc.(TSE:4589) added to S&P Global BMI Index

Acucela Inc. Reports Consolidated Earnings Results for the Six Months Ended June 30, 2016; Revises Earnings Guidance for Year Ending December 31, 2016

Acucela Inc. reported consolidated earnings results for the six months ended June 30, 2016. For the quarter, revenue from collaborations was JPY 682,293,000 against JPY 1,481,492,000 a year ago. Loss from operations was JPY 2,165,946,000 against JPY 1,457,515,000 a year ago. Loss before income tax was JPY 2,091,645,000 against JPY 1,407,809,000 a year ago. Net loss was JPY 2,093,395,000 against JPY 1,407,603,000 a year ago. Diluted loss per share was JPY 56 against JPY 39 a year ago. Net cash used in operating activities was JPY 1,610,362,000 against JPY 1,089,719,000 a year ago. Net additions to property and equipment were JPY 1,984,000 against JPY 49,397,000 a year ago. For the year ending December 31, 2016, the company expects revenue from collaborations of JPY 854,153,000 compared to previous forecast of JPY 2,830,025,000, loss from operations of JPY 3,941,453,000 compared to previous forecast of JPY 3,801,495,000, loss before income tax of JPY 3,797,379,000 compared to previous forecast of JPY 3,678,003,000 and net loss of JPY 3,797,379,000 or JPY 101 per share compared to previous forecast of JPY 3,678,003,000 or JPY 99 per share.

Acucela Inc., Board Meeting, Jul 12, 2016

Acucela Inc., Board Meeting, Jul 12, 2016. Agenda: To establish the record date and meeting date for its 2016 annual meeting of shareholders.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4589 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4589.
View Industry Companies
 

Industry Analysis

4589

Industry Average

Valuation 4589 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 28.9x
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 21.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ACUCELA INC, please visit www.acucela.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.